Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | CMA1 | P23946 | 18/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL30166493 | 1.00 | HSD17B10 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL719333 | 1.00 | HSD17B10 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL20528908 | 0.99 | HSD17B10 (0.99) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL3511220 | 0.94 | HSD17B10 (0.88) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL194013 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL14196602 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL49016 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL194012 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL49017 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL951858 | 0.88 | PTGS1 (0.99) | HSD17B10TDP1PTGS1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9024 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | claimed |
| US-12350376-B2 | Lyophilized powder of latamoxef sodium for injection and lyophilization method thereof | HAINAN HAILING CHEMIPHARMA CORPORATION LTD. (CN) | 2025-07-08 | — | — | US | claimed |
| US-12344622-B2 | Refining method of midbody of latamoxef sodium | HAINAN HAILING CHEMIPHARMA CORPORATION LTD. (CN) | 2025-07-01 | — | — | US | claimed |
| US-12312632-B2 | Systems and methods for performing antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2025-05-27 | — | — | US | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| CN-119606960-A | Application of sulbactam in preparation of medicines for treating novel coronavirus infection | 苏州大学附属第一医院 | 2025-03-14 | — | — | CN | claimed |
| US-20250025426-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2025-01-23 | — | — | US | claimed |
| EP-4472649-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES | AGS Therapeutics SAS (FR) | 2024-12-11 | — | — | EP | claimed |
| CN-112739307-B | Infusion system | 吴制药有限公司 | 2024-11-01 | — | — | CN | claimed |
| EP-4444275-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2024-10-16 | — | — | EP | claimed |
| EP-0263493-A2 | Pharmaceutic preparation to improve the gastro-intestinal resorption | F. HOFFMANN-LA ROCHE AG (CH) | 1988-04-13 | — | — | EP | claimed |
| US-4734279-A | Combination of immunoglobulins with therapeutic agents | BIOTEST PHARMA GMBH (DE) | 1988-03-29 | — | — | US | claimed |
| US-4684643-A | Pharmaceutical compositions for storage in plastic containers and process therefor | ELI LILLY AND COMPANY (US) | 1987-08-04 | — | — | US | claimed |
| US-4673637-A | ADMINISTERING ANTIBIOTIC EFFECTIVE AGAINST BACTERIA DETECTED | HYMAN EDWARD S | 1987-06-16 | — | — | US | claimed |
| US-4654331-A | Oral absorption enhancement of carboxylic acid pharmaceuticals using (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl ester group | MERCK & CO., INC. (US) | 1987-03-31 | — | — | US | claimed |
| EP-0059645-B1 | METHOD AND KIT FOR IDENTIFICATION OF BETA-LACTAMASES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-06-04 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| EP-0108295-A1 | Oral dosage form | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-05-16 | — | — | EP | claimed |
| WO-1982003090-A1 | METHOD AND KIT FOR IDENTIFICATION OF BETA-LACTAMASES | JAMES RICHARD | 1982-09-16 | — | — | WO | claimed |
| EP-0059645-A1 | Method and kit for identification of beta-lactamases | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-09-08 | — | — | EP | claimed |